Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia

NCT ID: NCT05125380

Last Updated: 2023-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall purpose of the project is to evaluate an algorithm for an HPV self-sampling based cervical cancer screening algorithm in a mid-size town in Ethiopia that could be applicable for nationwide implementation in low and middle-income countries (LMIC).

Specific aims are the following:

* To evaluate the algorithm using Visual Inspection with Acetic acid (VIA) and VIA together with Lugol's Iodine (VILI) as triage and to use HPV self-sample to follow up those treated and those with persisting HPV.
* To evaluate the prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and other STIs in the cohort.
* To determine immune response profiles in high-risk HPV-positive women who cleared, persisted, or developed Cervical Intraepithelial Neoplasia 2/3 (CIN).
* To assess how specific cervicovaginal microbiota compositions are associated with HPV infection, cervical dysplasia, and cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer STI Human Papilloma Virus Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

The whole cohort is offered an HPV self-sample. The HPV high risk positive women gets randomised into two arms VIA or VIA/VILI at the triage step.
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1- Triage arm for HPV pos women

HPV positive women

Group Type ACTIVE_COMPARATOR

VIA (Visual Inspection with Acetic acid)

Intervention Type DIAGNOSTIC_TEST

A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.

2- Triage arm for HPV pos women

HPV positive women

Group Type EXPERIMENTAL

VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)

Intervention Type DIAGNOSTIC_TEST

A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)

A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.

Intervention Type DIAGNOSTIC_TEST

VIA (Visual Inspection with Acetic acid)

A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Can give consent, Age above 18

Exclusion Criteria

* Women who have undergone hysterectomy
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Addis Ababa University

OTHER

Sponsor Role collaborator

Armauer Hansen Research Institute, Ethiopia

OTHER

Sponsor Role collaborator

Adama Hospital Medical College, Ethiopia

UNKNOWN

Sponsor Role collaborator

Lund University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adane Mihret, PhD

Role: PRINCIPAL_INVESTIGATOR

Armauer Hansen Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adama and Geda Health Center

Ādama, , Ethiopia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ethiopia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Selamawit Mekuria, MD

Role: CONTACT

+46720123974

Mats Jerkeman, MD, PhD

Role: CONTACT

+46704973507

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Adamu Meghersa

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Mekuria S, Assiged N, Biazin H, Borgfeldt C, Abebe T, Mihret A, Forslund O, Jerkeman M. Assessing the feasibility of HPV screening for cervical cancer in pregnant women in Ethiopia. Sci Rep. 2025 Aug 28;15(1):31771. doi: 10.1038/s41598-025-15957-y.

Reference Type DERIVED
PMID: 40877387 (View on PubMed)

Mekuria SF, Biazin H, Abebe T, Borgfeldt C, Assegid N, Mihret A, Obsi Nemomsa R, Forslund O, Jerkeman M. Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial. Int J Gynecol Cancer. 2024 Nov 4;34(11):1691-1697. doi: 10.1136/ijgc-2024-005694.

Reference Type DERIVED
PMID: 39362749 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FBKS 2019-6

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Screening for Early Cervical Cancer Detection
NCT06550583 ACTIVE_NOT_RECRUITING